Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
BCMA-targeted antibody-drug conjugate
DRUG CLASS:
BCMA-targeted antibody-drug conjugate
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
belantamab mafodotin-blmf (3)
HDP-101 (1)
MEDI2228 (0)
BMS-986352 (0)
belantamab mafodotin-blmf (3)
HDP-101 (1)
MEDI2228 (0)
BMS-986352 (0)
›
Associations
(4)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma (NCT05208307)
Phase 2
Emory University
Emory University
Recruiting
Phase 2
Emory University
Recruiting
Last update posted :
08/12/2024
Initiation :
07/21/2022
Primary completion :
10/21/2025
Completion :
10/21/2026
CD4
|
Chr t(4;14) • Chr t(14;16)
|
pomalidomide • Blenrep (belantamab mafodotin-blmf) • Hemady (dexamethasone tablets)
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3) (NCT04162210)
Phase 3
GlaxoSmithKline
GlaxoSmithKline
Active, not recruiting
Phase 3
GlaxoSmithKline
Active, not recruiting
Last update posted :
06/10/2024
Initiation :
04/02/2020
Primary completion :
09/12/2022
Completion :
06/26/2025
CD4
|
dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma (NCT05065047)
Phase 1
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Recruiting
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/08/2024
Initiation :
01/05/2023
Primary completion :
05/01/2025
Completion :
05/01/2025
CD4
|
Blenrep (belantamab mafodotin-blmf)
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment (NCT05556798)
Phase 1
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Recruiting
Phase 1
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
05/07/2024
Initiation :
10/04/2022
Primary completion :
10/01/2026
Completion :
10/01/2026
SDC1
|
pomalidomide • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (COSTA) (NCT05874193)
Phase 2
Cristiana Costa Chase, DO
Cristiana Costa Chase, DO
Not yet recruiting
Phase 2
Cristiana Costa Chase, DO
Not yet recruiting
Last update posted :
04/22/2024
Initiation :
06/01/2024
Primary completion :
09/01/2025
Completion :
09/01/2027
CD4
|
Blenrep (belantamab mafodotin-blmf)
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT04177823)
Phase 1
GlaxoSmithKline
GlaxoSmithKline
Completed
Phase 1
GlaxoSmithKline
Completed
Last update posted :
04/19/2024
Initiation :
12/09/2019
Primary completion :
12/30/2022
Completion :
12/30/2022
CD8
|
CD38 positive
|
Blenrep (belantamab mafodotin-blmf)
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (EAE120) (NCT05280275)
Phase 1/2
Hellenic Society of Hematology
Hellenic Society of Hematology
Recruiting
Phase 1/2
Hellenic Society of Hematology
Recruiting
Last update posted :
12/01/2023
Initiation :
04/13/2022
Primary completion :
03/15/2026
Completion :
03/15/2026
CD4
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (BelaRd) (NCT04808037)
Phase 1/2
Hellenic Society of Hematology
Hellenic Society of Hematology
Active, not recruiting
Phase 1/2
Hellenic Society of Hematology
Active, not recruiting
Last update posted :
10/24/2023
Initiation :
02/22/2021
Primary completion :
09/08/2028
Completion :
11/08/2028
CD4
|
lenalidomide • dexamethasone • Blenrep (belantamab mafodotin-blmf) • dexamethasone injection
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma (NCT05573802)
Phase 1/2
Hellenic Society of Hematology
Hellenic Society of Hematology
Recruiting
Phase 1/2
Hellenic Society of Hematology
Recruiting
Last update posted :
10/24/2023
Initiation :
07/14/2023
Primary completion :
10/31/2026
Completion :
10/31/2026
CD4
|
lenalidomide • dexamethasone • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory (NCT05581875)
Phase 1/2
Hellenic Society of Hematology
Hellenic Society of Hematology
Not yet recruiting
Phase 1/2
Hellenic Society of Hematology
Not yet recruiting
Last update posted :
10/17/2022
Initiation :
10/20/2022
Primary completion :
10/31/2026
Completion :
10/31/2026
CD4
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (GEM-BELA-VRd) (NCT04802356)
Phase 2
PETHEMA Foundation
PETHEMA Foundation
Recruiting
Phase 2
PETHEMA Foundation
Recruiting
Last update posted :
12/06/2021
Initiation :
04/07/2021
Primary completion :
03/01/2025
Completion :
07/01/2025
CD34
|
lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login